PDF(Pubmed)
Abstract：
UNASSIGNED: Several effective vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and implemented in the population. However, the current production capacity falls short of meeting global demand. Therefore, it is crucial to further develop novel vaccine platforms that can bridge the distribution gap. AVX/COVID-12 is a vector-based vaccine that utilizes the Newcastle Disease virus (NDV) to present the SARS-CoV-2 spike protein to the immune system.
UNASSIGNED: This study aims to analyze the antigenicity of the vaccine candidate by examining antibody binding and T-cell activation in individuals infected with SARS-CoV-2 or variants of concern (VOCs), as well as in healthy volunteers who received coronavirus disease 2019 (COVID-19) vaccinations.
UNASSIGNED: Our findings indicate that the vaccine effectively binds antibodies and activates T-cells in individuals who received 2 or 3 doses of BNT162b2 or AZ/ChAdOx-1-S vaccines. Furthermore, the stimulation of T-cells from patients and vaccine recipients with AVX/COVID-12 resulted in their proliferation and secretion of interferon-gamma (IFN-γ) in both CD4+ and CD8+ T-cells.
UNASSIGNED: The AVX/COVID-12 vectored vaccine candidate demonstrates the ability to stimulate robust cellular responses and is recognized by antibodies primed by the spike protein present in SARS-CoV-2 viruses that infected patients, as well as in the mRNA BNT162b2 and AZ/ChAdOx-1-S vaccines. These results support the inclusion of the AVX/COVID-12 vaccine as a booster in vaccination programs aimed at addressing COVID-19 caused by SARS-CoV-2 and its VOCs.
UNASSIGNED: This study aims to analyze the antigenicity of the vaccine candidate by examining antibody binding and T-cell activation in individuals infected with SARS-CoV-2 or variants of concern (VOCs), as well as in healthy volunteers who received coronavirus disease 2019 (COVID-19) vaccinations.
UNASSIGNED: Our findings indicate that the vaccine effectively binds antibodies and activates T-cells in individuals who received 2 or 3 doses of BNT162b2 or AZ/ChAdOx-1-S vaccines. Furthermore, the stimulation of T-cells from patients and vaccine recipients with AVX/COVID-12 resulted in their proliferation and secretion of interferon-gamma (IFN-γ) in both CD4+ and CD8+ T-cells.
UNASSIGNED: The AVX/COVID-12 vectored vaccine candidate demonstrates the ability to stimulate robust cellular responses and is recognized by antibodies primed by the spike protein present in SARS-CoV-2 viruses that infected patients, as well as in the mRNA BNT162b2 and AZ/ChAdOx-1-S vaccines. These results support the inclusion of the AVX/COVID-12 vaccine as a booster in vaccination programs aimed at addressing COVID-19 caused by SARS-CoV-2 and its VOCs.
摘要：
■已经开发并在人群中实施了几种有效的严重急性呼吸道综合症冠状病毒2（SARS-CoV-2）疫苗。然而,目前的生产能力不足以满足全球需求。因此,进一步开发能够弥合分布差距的新型疫苗平台至关重要。AVX/COVID-12是一种基于载体的疫苗，它利用新城疫病毒（NDV）将SARS-CoV-2刺突蛋白提供给免疫系统。
■本研究旨在通过检查感染SARS-CoV-2或关注变种（VOC）的个体的抗体结合和T细胞活化来分析候选疫苗的抗原性，以及接受2019年冠状病毒病（COVID-19）疫苗接种的健康志愿者。
■我们的发现表明，该疫苗有效结合抗体并激活接受2或3剂BNT162b2或AZ/ChAdOx-1-S疫苗的个体的T细胞。此外，用AVX/COVID-12刺激患者和疫苗接受者的T细胞,导致其在CD4+和CD8+T细胞中增殖和分泌干扰素-γ(IFN-γ).
AVX/COVID-12载体疫苗候选物显示出刺激强烈细胞反应的能力，并被感染患者的SARS-CoV-2病毒中存在的刺突蛋白引发的抗体识别，以及BNT162b2mRNA和AZ/ChAdOx-1-S疫苗。这些结果支持将AVX/COVID-12疫苗纳入疫苗接种计划，旨在解决SARS-CoV-2及其挥发性有机化合物引起的COVID-19。
■本研究旨在通过检查感染SARS-CoV-2或关注变种（VOC）的个体的抗体结合和T细胞活化来分析候选疫苗的抗原性，以及接受2019年冠状病毒病（COVID-19）疫苗接种的健康志愿者。
■我们的发现表明，该疫苗有效结合抗体并激活接受2或3剂BNT162b2或AZ/ChAdOx-1-S疫苗的个体的T细胞。此外，用AVX/COVID-12刺激患者和疫苗接受者的T细胞,导致其在CD4+和CD8+T细胞中增殖和分泌干扰素-γ(IFN-γ).
AVX/COVID-12载体疫苗候选物显示出刺激强烈细胞反应的能力，并被感染患者的SARS-CoV-2病毒中存在的刺突蛋白引发的抗体识别，以及BNT162b2mRNA和AZ/ChAdOx-1-S疫苗。这些结果支持将AVX/COVID-12疫苗纳入疫苗接种计划，旨在解决SARS-CoV-2及其挥发性有机化合物引起的COVID-19。
